Tectonic Therapeutic Advances in Pulmonary Hypertension Trials

Tectonic Therapeutic (TECX) has shared an update.

Tectonic Therapeutic, Inc. has announced the FDA’s clearance of its IND application for TX45, a promising treatment for Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction. As the company progresses, investors and analysts can expect the release of Phase 1a clinical trial results in September 2024 and Phase 1b results by mid-2025. Furthermore, a global Phase 2 clinical trial is set to begin in the third quarter of 2024. This update signifies a significant milestone for Tectonic Therapeutic, potentially impacting its stock as it advances through the clinical trial phases.

For detailed information about TECX stock, go to TipRanks’ Stock Analysis page.